Stock 2496 WUHAN YZY BIOPHARMA CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Wuhan YZY Biopharma Co., Ltd.

Equities

2496

CNE1000063C4

Biotechnology & Medical Research

Delayed Hong Kong S.E.
Other stock markets
 09:08:07 03/06/2024 BST 		5-day change 1st Jan Change
7.45 HKD 0.00% Intraday chart for Wuhan YZY Biopharma Co., Ltd. 0.00% -16.29%
05-24 Wuhan Yzy Biopharma Presents Clinical Trial Data of Tumor Drug at Cancer Conference MT
05-24 Wuhan YZY Biopharma Co., Ltd. Announces Phase II Study Data of M701 for the Treatment of Malignant Ascites Presented At the 2024 ASCO Meeting CI
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In

Latest news about Wuhan YZY Biopharma Co., Ltd.

Wuhan Yzy Biopharma Presents Clinical Trial Data of Tumor Drug at Cancer Conference MT
Wuhan YZY Biopharma Co., Ltd. Announces Phase II Study Data of M701 for the Treatment of Malignant Ascites Presented At the 2024 ASCO Meeting CI
YZY Biopharma Co., Ltd. Announces Resignation of Liu Dan as Non-Executive Director CI
Wuhan YZY Biopharma Co., Ltd. Announces the First Patient Enrolled in Phase III Clinical Trial of M701 CI
Wuhan Yzy Biopharma Enrolls First Participant in Cancer Drug's Phase II Clinical Trial MT
Wuhan YZY Biopharma Co., Ltd. Announces the First Patient Has Recently Been Enrolled in A Phase Ii Clinical Trial of M701 CI
Wuhan YZY Biopharma Co., Ltd. Announces Change of Employee Representative Supervisor CI
Wuhan YZY Biopharma Discloses Partial Exercise of IPO's Over-Allotment; Shares Slump 15% MT
Wuhan YZY Biopharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
China Evergrande Debt Troubles Drag Hong Kong Stocks; Wuhan YZY Biopharma Closes Flat, LC Logistics Slip in Debut MT
Wuhan YZY Biopharma Raises HK$121 Million in Hong Kong IPO, Prices at Bottom of Range MT

Chart Wuhan YZY Biopharma Co., Ltd.

Chart Wuhan YZY Biopharma Co., Ltd.
More charts

Company Profile

Wuhan YZY Biopharma Co Ltd is a China-based company principally engaged in the research, development, production and sales of pharmaceuticals. The Company is mainly engaged in the research, development and industrialization of bispecific antibody drugs. The Company's main products include anti-PD1&anti-CD3, anti-CD19&anti-CD3, and anti-CDX&CD3. The Company's drug products are mainly used in major diseases such as tumor, immunity, inflammation, cardiovascular and infection.
Sector
Biotechnology & Medical Research
More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

1st Jan change Capi.
WUHAN YZY BIOPHARMA CO., LTD. Stock Wuhan YZY Biopharma Co., Ltd.
-16.29% 185M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+15.55% 121B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.66% 107B
BIONTECH SE Stock BioNTech SE
-2.53% 24.82B
ARGENX SE Stock argenx SE
+1.14% 22.48B
GENMAB A/S Stock Genmab A/S
-9.35% 18.32B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.28% 16.33B
BEIGENE, LTD. Stock BeiGene, Ltd.
-18.92% 15.31B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.19% 14.08B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+28.83% 11.74B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 2496 Stock
  4. News Wuhan YZY Biopharma Co., Ltd.
  5. Wuhan YZY Biopharma Discloses Partial Exercise of IPO's Over-Allotment; Shares Slump 15%
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW